<- Go Home
BioVie Inc.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Market Cap
$53.2M
Volume
138.5K
Cash and Equivalents
$20.0M
EBITDA
-$25.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$56.20
52 Week Low
$1.04
Dividend
N/A
Price / Book Value
1.70
Price / Earnings
-0.58
Price / Tangible Book Value
1.79
Enterprise Value
$36.9M
Enterprise Value / EBITDA
-1.47
Operating Income
-$25.4M
Return on Equity
236.52%
Return on Assets
-70.63
Cash and Short Term Investments
$20.0M
Debt
$3.7M
Equity
$14.1M
Revenue
N/A
Unlevered FCF
-$10.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium